The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on the offspring

Frontiers in Cellular Neuroscience

Volumn , Issue MAY, 2013, Pages

  Olivier, J D A ^a,b   Akerud H ^a   Kaihola, H ^a   Pawluski, J L ^c   Skalkidou, A ^a   Hogberg U ^a   Sundstrom Poromaa I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

5 HTT; Maternal depression; Neurodevelopment; Serotonin; SSRI

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HOMOVANILLIC ACID; NORADRENALIN; NORFLUOXETINE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ZIMELDINE;

ANENCEPHALUS; ANUS ATRESIA; AUTISM; BEHAVIOR DISORDER; BODY TEMPERATURE DISORDER; CLUBFOOT; CONCENTRATION (PARAMETERS); CONGENITAL HEART MALFORMATION; CONVULSION; CRANIOFACIAL SYNOSTOSIS; CRYPTORCHISM; DISEASE ASSOCIATION; DRUG USE; ENVIRONMENTAL EXPOSURE; FEEDING DISORDER; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; HYPOGLYCEMIA; INFANTILE SPASM; INTELLIGENCE QUOTIENT; INTRAUTERINE GROWTH RETARDATION; IRRITABILITY; JAUNDICE; LANGUAGE DEVELOPMENT; LIMB REDUCTION DEFECT; LOW BIRTH WEIGHT; MENTAL PERFORMANCE; METABOLITE; MOTOR DEVELOPMENT; NEURAL TUBE DEFECT; NEWBORN INTENSIVE CARE; NONHUMAN; OMPHALOCELE; PERSISTENT PULMONARY HYPERTENSION; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRESCRIPTION; PROGENY; PSYCHOMOTOR DEVELOPMENT; PUERPERAL DEPRESSION; REM SLEEP DEPRIVATION; RESPIRATORY DISTRESS; RESTLESSNESS; REVIEW; RIGIDITY; SEROTONIN BLOOD LEVEL; SEROTONIN TRANSPORTER GENE; SHIVERING; SLEEP DISORDER; SLEEP WAKING CYCLE; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; STRESS; TEMPERAMENT; TREMOR; UMBILICAL CORD BLOOD;

EID: 84877251615     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2013.00073     Document Type: Review

References (177)

1. Andersson, L., Sundstrom-Poromaa I., Bixo M., Wulff M., Bondestam K., aStrom M. (2003). Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 189, 148-154.
2. Andersson, L., Sundstrom-Poromaa I., Wulff M., aStrom M., Bixo M. (2004). Implications of antenatal depression and anxiety for obstetric outcome. Obstet Gynecol 104, 467-476.
3. Andrade, S.E., McPhillips H., Loren D., Raebel M.A., Lane K., Livingston J., Boudreau D.M., Smith D.H., Davis R.L., Willy M.E., Platt R. (2009). Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 18, 246-252.
4. Andrews, M.H., Matthews S.G. (2004). Programming of the hypothalamo-pituitary-adrenal axis: serotonergic involvement. Stress 7, 15-27.
5. Ansorge, M.S., Hen R., Gingrich J.A. (2007). Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol 7, 8-17.
6. Ansorge, M.S., Morelli E., Gingrich J.A. (2008). Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 28, 199-207.
7. Ansorge, M.S., Zhou M., Lira A., Hen R., Gingrich J.A. (2004). Early-life blockade of the 5- HT transporter alters emotional behavior in adult mice. science 306, 879-881.
8. Atkinson, H.C., Waddell B.J. (1997). Circadian variation in basal plasma corticosterone and adrenocorticotropin in the rat: sexual dimorphism and changes across the estrous cycle. Endocrinology 138, 3842-3848.
9. Bairy, K.L., Madhyastha S., Ashok K.P., Bairy I., Malini S. (2007). Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 79, 1-11.
10. Barbey, J.T., Roose S.P. (1998). SSRI safety in overdose. J Clin Psychiatry 59 Suppl 15, 42-48.
11. Baumann, P., Rochat B. (1995). Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 10 Suppl 1, 15-21.
12. Belik, J. (2008). Fetal and neonatal effects of maternal drug treatment for depression. Semin Perinatol 32, 350-354.
13. Belsky, J., Jonassaint C., Pluess M., Stanton M., Brummett B., Williams R. (2009). Vulnerability genes or plasticity genes? Mol Psychiatry 14, 746-754.
14. Bonari, L., Pinto N., Ahn E., Einarson A., Steiner M., Koren G. (2004). Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49, 726-735.
15. Brennan, P.A., Pargas R., Walker E.F., Green P., Newport D.J., Stowe Z. (2008). Maternal depression and infant cortisol: influences of timing, comorbidity and treatment. J Child Psychol Psychiatry 49, 1099-1107.
16. Brigman, J.L., Mathur P., Harvey-White J., Izquierdo A., Saksida L.M., Bussey T.J., Fox S., Deneris E., Murphy D.L., Holmes A. (2010). Pharmacological or Genetic Inactivation of the Serotonin Transporter Improves Reversal Learning in Mice. Cereb Cortex.
17. Cabrera, T.M., Battaglia G. (1994). Delayed decreases in brain 5-hydroxytryptamine2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J Pharmacol Exp Ther 269, 637-645.
18. Casper, R.C., Fleisher B.E., Lee-Ancajas J.C., Gilles A., Gaylor E., DeBattista A., Hoyme H.E. (2003). Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142, 402-408.
19. Caspi, A., Hariri A.R., Holmes A., Uher R., Moffitt T.E. (2010). Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 167, 509-527.
20. Caspi, A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. science 301, 386-389.
21. Chambers, C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., Mitchell A.A. (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354, 579-587.
22. Chambers, C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. (1996). Birth outcomes in pregnant women taking fluoxetine. NEngl J Med 335, 1010-1015.
23. Chung, T.K., Lau T.K., Yip A.S., Chiu H.F., Lee D.T. (2001). Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 63, 830-834.
24. Clubb, F.J., Jr., Bishop S.P. (1984). Formation of binucleated myocardial cells in the neonatal rat. An index for growth hypertrophy. Lab Invest 50, 571-577.
25. Cohen, L.S., Altshuler L.L., Harlow B.L., Nonacs R., Newport D.J., Viguera A.C., Suri R., Burt V.K., Hendrick V., Reminick A.M., Loughead A., Vitonis A.F., Stowe Z.N. (2006). Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295, 499-507.
26. Cohen, L.S., Heller V.L., Bailey J.W., Grush L., Ablon J.S., Bouffard S.M. (2000). Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 48, 996-1000.
27. Cole, J.A., Ephross S.A., Cosmatos I.S., Walker A.M. (2007). Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16, 1075-1085.
28. Cooper, W.O., Willy M.E., Pont S.J., Ray W.A. (2007). Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196, 544-545.
29. Costei, A.M., Kozer E., Ho T., Ito S., Koren G. (2002). Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr AdolescMed 156, 1129-1132.
30. Croen, L.A., Grether J.K., Yoshida C.K., Odouli R., Hendrick V. (2011). Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 68, 1104-1112.
31. Davis, E.P., Sandman C.A. (2012). Prenatal psychobiological predictors of anxiety risk in preadolescent children. Psychoneuroendocrinology 37, 1224-1233.
32. Davis, R.L., Rubanowice D., McPhillips H., Raebel M.A., Andrade S.E., Smith D., Yood M.U., Platt R. (2007). Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 16, 1086-1094.
33. Diav-Citrin, O., Shechtman S., Weinbaum D., Arnon J., di Gianantonio E., Clementi M., Ornoy A. (2008). Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reprod Toxicol 20, 459.
34. DiPietro, J.A. (2012). Maternal stress in pregnancy: considerations for fetal development. J Adolesc Health 51, S3-S8.
35. DiPietro, J.A., Novak M.F., Costigan K.A., Atella L.D., Reusing S.P. (2006). Maternal psychological distress during pregnancy in relation to child development at age two. Child Dev 77, 573-587.
36. Dubovicky, M., Csaszarova E., Brnoliakova Z., Ujhazy E., Navarova J., Mach M. (2012). Effect of prenatal administration of venlafaxine on postnatal development of rat offspring. Interdiscip Toxicol 5, 92-97.
37. Eddahibi, S., Hanoun N., Lanfumey L., Lesch K.P., Raffestin B., Hamon M., Adnot S. (2000). Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105, 1555-1562.
38. Einarson, T.R., Einarson A. (2005). Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 14, 823-827.
39. El Marroun, H., Jaddoe V.W., Hudziak J.J., Roza S.J., Steegers E.A., Hofman A., Verhulst F.C., White T.J., Stricker B.H., Tiemeier H. (2012). Maternal Use of Selective Serotonin Reuptake Inhibitors, Fetal Growth, and Risk of Adverse Birth Outcomes. Arch Gen Psychiatry.
40. Ellfolk, M., Malm H. (2010). Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 30, 249-260.
41. Ericson, A., Kallen B., Wiholm B. (1999). Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 55, 503-508.
42. Favreliere, S., Nourrisson A., Jaafari N., Perault Pochat M.C. (2010). [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn]. Encephale 36 Suppl 2, D133-D138.
43. Fornaro, E., Li D., Pan J., Belik J. (2007). Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am JRespir Crit Care Med 176, 1035-1040.
44. Fricker, A.D., Rios C., Devi L.A., Gomes I. (2005). Serotonin receptor activation leads to neurite outgrowth and neuronal survival. Brain Res Mol Brain Res 138, 228-235.
45. Gaspar, P., Cases O., Maroteaux L. (2003). The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 4, 1002-1012.
46. Gentile, S. (2005). SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 19, 623-633.
47. Gorman, L.L., O'Hara M.W., Figueiredo B., Hayes S., Jacquemain F., Kammerer M.H., Klier C.M., Rosi S., Seneviratne G., Sutter-Dallay A.L. (2004). Adaptation of the structured clinical interview for DSM-IV disorders for assessing depression in women during pregnancy and post-partum across countries and cultures. Br J Psychiatry Suppl 46, s17-s23.
48. Grote, N.K., Bridge J.A., Gavin A.R., Melville J.L., Iyengar S., Katon W.J. (2010). A metaanalysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 67, 1012-1024.
49. Guidotti, G., Calabrese F., Auletta F., Olivier J., Racagni G., Homberg J., Riva M.A. (2012). Developmental influence of the serotonin transporter on the expression of npas4 and GABAergic markers: modulation by antidepressant treatment. Neuropsychopharmacology 37, 746-758.
50. Hankin, B.L., Nederhof E., Oppenheimer C.W., Jenness J., Young J.F., Abela J.R., Smolen A., Ormel J., Oldehinkel A.J. (2011). Differential susceptibility in youth: evidence that 5- HTTLPR x positive parenting is associated with positive affect 'for better and worse'. Transl Psychiatry 1, e44.
51. Hanley, G.E., Oberlander T.F. (2012). Neurodevelopmental outcomes following prenatal exposure to serotonin reuptake inhibitor antidepressants: a social teratogen or moderator of developmental risk? Birth Defects Res A Clin Mol Teratol 94, 651-659.
52. Hansen, H.H., Mikkelsen J.D. (1998). Long-term effects on serotonin transporter mRNA expression of chronic neonatal exposure to a serotonin reuptake inhibitor. Eur J Pharmacol 352, 307-315.
53. Hansen, H.H., Sanchez C., Meier E. (1997). Neonatal administration of the selective serotonin reuptake inhibitor Lu 10-134-C increases forced swimming-induced immobility in adult rats: a putative animal model of depression? J Pharmacol Exp Ther 283, 1333-1341.
54. Haskell, S.E., Hermann G.M., Reinking B.E., Volk K.A., Reona V.A., Zhu V., Roghaii R.D. (2012). Sertraline exposure leads to small left heart syndrome in adult mice. Pediatr Res.
55. Hay, D.F., Pawlby S., Waters C.S., Sharp D. (2008). Antepartum and postpartum exposure to maternal depression: different effects on different adolescent outcomes. J Child Psychol Psychiatry 49, 1079-1088.
56. Hayes, R.M., Wu P., Shelton R.C., Cooper W.O., Dupont W.D., Mitchel E., Hartert T.V. (2012). Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol 207, 49.
57. Heikkinen, T., Ekblad U., Palo P., Laine K. (2003). Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 73, 330-337.
58. Hemels, M.E., Einarson A., Koren G., Lanctot K.L., Einarson T.R. (2005). Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 39, 803-809.
59. Hendrick, V., Smith L.M., Suri R., Hwang S., Haynes D., Altshuler L. (2003a). Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 188, 812-815.
60. Hendrick, V., Stowe Z.N., Altshuler L.L., Hwang S., Lee E., Haynes D. (2003b). Placental passage of antidepressant medications. Am J Psychiatry 160, 993-996.
61. Henrichs, J., Schenk J.J., Roza S.J., van den Berg M.P., Schmidt H.G., Steegers E.A., Hofman A., Jaddoe V.W., Verhulst F.C., Tiemeier H. (2010). Maternal psychological distress and fetal growth trajectories: the Generation R Study. Psychol Med 40, 633-643.
62. Hernandez-Diaz, S., Van Marter L.J., Werler M.M., Louik C., Mitchell A.A. (2007). Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 120, e272-e282.
63. Hibbard, J.U., Wilkins I., Sun L., Gregory K., Haberman S., Hoffman M., Kominiarek M.A., Reddy U., Bailit J., Branch D.W., Burkman R., Gonzalez Quintero V.H., Hatjis C.G., Landy H., Ramirez M., VanVeldhuisen P., Troendle J., Zhang J. (2010). Respiratory morbidity in late preterm births. JAMA 304, 419-425.
64. Hilakivi, I., Ahtee L., Rinne J.O., Taira T., Attila L.M., Marjamaki P. (1995). Effects of monoamine uptake inhibitors given early postnatally on monoamines in the brain stem, caudate/putamen and cortex, and on dopamine D1 and D2 receptors in the caudate/putamen. J Neural Transm Gen Sect 102, 139-148.
65. Homberg, J.R., Lesch K.P. (2011). Looking on the bright side of serotonin transporter gene variation. Biol Psychiatry 69, 513-519.
66. Homberg, J.R., Schubert D., Gaspar P. (2010). New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 31, 60-65.
67. Hyttel, J. (1994). Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9 Suppl 1, 19-26.
68. Isbister, G.K., Dawson A., Whyte I.M., Prior F.H., Clancy C., Smith A.J. (2001). Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 85, F147-F148.
69. Ishiwata, H., Shiga T., Okado N. (2005). Selective serotonin reuptake inhibitor treatment of early postnatal mice reverses their prenatal stress-induced brain dysfunction. Neuroscience 133, 893-901.
70. Jablensky, A.V., Morgan V., Zubrick S.R., Bower C., Yellachich L.A. (2005). Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 162, 79-91.
71. Johnson, G.L. (1997). Birth outcomes in pregnant women taking fluoxetine. JFam Pract 44, 32.
72. Kallen, B. (2004). Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr AdolescMed 158, 312-316.
73. Kallen, B., Olausson P.O. (2008). Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 17, 801-806.
74. Kallen, B.A., Otterblad O.P. (2007). Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79, 301-308.
75. Kalueff, A.V., Olivier J.D., Nonkes L.J., Homberg J.R. (2010). Conserved role for the serotonin transporter gene in rat and mouse neurobehavioral endophenotypes. Neurosci Biobehav Rev 34, 373-386.
76. Kendler, K.S., Kuhn J.W., Vittum J., Prescott C.A., Riley B. (2005). The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 62, 529-535.
77. Kieler, H. (2012). Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries.
78. Kim, C.W., Choe C., Kim E.J., Lee J.I., Yoon S.Y., Cho Y.W., Han S., Tak H.M., Han J., Kang D. (2012). Dual effects of fluoxetine on mouse early embryonic development. Toxicol Appl Pharmacol 265, 61-72.
79. Kinnally, E.L., Capitanio J.P., Leibel R., Deng L., Leduc C., Haghighi F., Mann J.J. (2010). Epigenetic Regulation of Serotonin Transporter Expression and Behavior in Infant Rhesus Macaques. Genes Brain Behav.
80. Knaepen, L., Rayen I., Charlier T.D., Fillet M., Houbart V., van K.M., Steinbusch H.W., Patijn J., Tibboel D., Joosten E.A., Pawluski J.L. (2013). Developmental fluoxetine exposure normalizes the long-term effects of maternal stress on post-operative pain in Sprague-Dawley rat offspring. PLoS ONE 8, e57608.
81. Kulin, N.A., Pastuszak A., Sage S.R., Schick-Boschetto B., Spivey G., Feldkamp M., Ormond K., Matsui D., Stein-Schechman A.K., Cook L., Brochu J., Rieder M., Koren G. (1998). Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 279, 609-610.
82. Kurki, T., Hiilesmaa V., Raitasalo R., Mattila H., Ylikorkala O. (2000). Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 95, 487-490.
83. Kusakawa, S., Yamauchi J., Miyamoto Y., Sanbe A., Tanoue A. (2008). Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system. Life Sci 83, 871-877.
84. Laine, K., Heikkinen T., Ekblad U., Kero P. (2003). Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 60, 720-726.
85. Laplante, P., Diorio J., Meaney M.J. (2002). Serotonin regulates hippocampal glucocorticoid receptor expression via a 5-HT7 receptor. Brain Res Dev Brain Res 139, 199-203.
86. Lattimore, K.A., Donn S.M., Kaciroti N., Kemper A.R., Neal C.R., Jr., Vazquez D.M. (2005). Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 25, 595-604.
87. Lee, L.J. (2009). Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotox Res 15, 212-223.
88. Lesch, K.P. (2007). Linking emotion to the social brain. The role of the serotonin transporter in human social behaviour. EMBO Rep 8 Spec No, S24-S29.
89. Lesch, K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. science 274, 1527-1531.
90. Levinson-Castiel, R., Merlob P., Linder N., Sirota L., Klinger G. (2006). Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160, 173-176.
91. Lisboa, S.F., Oliveira P.E., Costa L.C., Venancio E.J., Moreira E.G. (2007). Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 80, 49-56.
92. Louik, C., Lin A.E., Werler M.M., Hernandez-Diaz S., Mitchell A.A. (2007). First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356, 2675-2683.
93. Lund, N., Pedersen L.H., Henriksen T.B. (2009). Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 163, 949-954.
94. Lundmark, J., Reis M., Bengtsson F. (2001). Serum concentrations of fluoxetine in the clinical treatment setting. Ther DrugMonit 23, 139-147.
95. Maciag, D., Simpson K.L., Coppinger D., Lu Y., Wang Y., Lin R.C., Paul I.A. (2006). Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 31, 47-57.
96. MacLean, M.R., Deuchar G.A., Hicks M.N., Morecroft I., Shen S., Sheward J., Colston J., Loughlin L., Nilsen M., Dempsie Y., Harmar A. (2004). Overexpression of the 5- hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia- induced pulmonary hypertension. Circulation 109, 2150-2155.
97. Malm, H., Klaukka T., Neuvonen P.J. (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106, 1289-1296.
98. Manhaes de Castro, R., Barreto Medeiros J.M., Mendes da Silva C., Ferreira L.M., Guedes R.C., Cabral Filho J.E., Costa J.A. (2001). Reduction of intraspecific aggression in adult rats by neonatal treatment with a selective serotonin reuptake inhibitor. Braz J Med Biol Res 34, 121-124.
99. Meaney, M.J., Diorio J., Francis D., LaRocque S., O'Donnell D., Smythe J.W., Sharma S., Tannenbaum B. (1994). Environmental regulation of the development of glucocorticoid receptor systems in the rat forebrain. The role of serotonin. Ann N YAcad Sci 746, 260-273.
100. Melville, J.L., Gavin A., Guo Y., Fan M.Y., Katon W.J. (2010). Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample. Obstet Gynecol 116, 1064-1070.
101. Miller, L.J., LaRusso E.M. (2011). Preventing postpartum depression. Psychiatr Clin North Am 34, 53-65.
102. Mirmiran, M., van de Poll N.E., Corner M.A., van Oyen H.G., Bour H.L. (1981). Suppression of active sleep by chronic treatment with chlorimipramine during early postnatal development: effects upon adult sleep and behavior in the rat. Brain Res 204, 129-146.
103. Misri, S., Reebye P., Kendrick K., Carter D., Ryan D., Grunau R.E., Oberlander T.F. (2006). Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 163, 1026-1032.
104. Molteni, R., Calabrese F., Maj P.F., Olivier J.D., Racagni G., Ellenbroek B.A., Riva M.A. (2009). Altered expression and modulation of activity-regulated cytoskeletal associated protein (Arc) in serotonin transporter knockout rats. Eur Neuropsychopharmacol 19, 898-904.
105. Molteni, R., Cattaneo A., Calabrese F., Macchi F., Olivier J.D., Racagni G., Ellenbroek B.A., Gennarelli M., Riva M.A. (2010). Reduced function of the serotonin transporter is associated with decreased expression of BDNF in rodents as well as in humans. Neurobiol Dis 37, 747-755.
106. Morrison, J.L., Riggs K.W., Chien C., Gruber N., McMillen I.C., Rurak D.W. (2004). Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes. Pediatr Res 56, 40-46.
107. Mortensen, J.T., Olsen J., Larsen H., Bendsen J., Obel C., Sorensen H.T. (2003). Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol 18, 769-771.
108. Moses-Kolko, E.L., Bogen D., Perel J., Bregar A., Uhl K., Levin B., Wisner K.L. (2005). Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293, 2372-2383.
109. Murphy, D.L., Lesch K.P. (2008). Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci 9, 85-96.
110. Murray, L., Cooper P.J. (1997). Postpartum depression and child development. Psychol Med 27, 253-260.
111. Nonkes, L.J., Maes J.H., Homberg J.R. (2011). Improved cognitive flexibility in serotonin transporter knockout rats is unchanged following chronic cocaine self-administration. Addict Biol.
112. Nonkes, L.J., van de Vondervoort I.I., de Leeuw M.J., Wijlaars L.P., Maes J.H., Homberg J.R. (2012). Serotonin transporter knockout rats show improved strategy set-shifting and reduced latent inhibition. Learn Mem 19, 190-193.
113. Noorlander, C.W., Ververs F.F., Nikkels P.G., van Echteld C.J., Visser G.H., Smidt M.P. (2008). Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE 3, e2782.
114. Nulman, I., Rovet J., Stewart D.E., Wolpin J., Gardner H.A., Theis J.G., Kulin N., Koren G. (1997). Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336, 258-262.
115. Nulman, I., Rovet J., Stewart D.E., Wolpin J., Pace-Asciak P., Shuhaiber S., Koren G. (2002). Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159, 1889-1895.
116. O'Connor, T.G., Heron J., Glover V. (2002). Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J Am Acad Child Adolesc Psychiatry 41, 1470-1477.
117. Oberlander, T.F., Bonaguro R.J., Misri S., Papsdorf M., Ross C.J., Simpson E.M. (2008a). Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 13, 65-73.
118. Oberlander, T.F., Eckstein G.R., Fitzgerald C., Ellwood A.L., Misri S., Rurak D., Riggs K.W. (2002). Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 51, 443-453.
119. Oberlander, T.F., Grunau R., Mayes L., Riggs W., Rurak D., Papsdorf M., Misri S., Weinberg J. (2008b). Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 84, 689-697.
120. Oberlander, T.F., Grunau R.E., Fitzgerald C., Papsdorf M., Rurak D., Riggs W. (2005). Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 115, 411-425.
121. Oberlander, T.F., Papsdorf M., Brain U.M., Misri S., Ross C., Grunau R.E. (2010). Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med 164, 444-451.
122. Oberlander, T.F., Reebye P., Misri S., Papsdorf M., Kim J., Grunau R.E. (2007). Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 161, 22-29.
123. Oberlander, T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. (2006). Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63, 898-906.
124. Oberlander, T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. (2008c). Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 192, 338-343.
125. Oberlander, T.F., Warburton W., Misri S., Riggs W., Aghajanian J., Hertzman C. (2008d). Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 83, 68-76.
126. Olivier, J.D.A., Valles A., van Heesch F., Afrasiab-Middelman A., Roelofs J.J.P.M., Jonkers M., Peeters E.J., Korte-Bouws G.A.H., Dederen P., Kiliaan A.J., Martens G.J., Schubert D., Homberg J.R. (2011). Fluoxetine administration to pregnant rats has long-term consequences for the offspring. Psychopharmacology (Berl) 217, 419-432.
127. Orr, S.T., Miller C.A. (1995). Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 17, 165-171.
128. Palmsten, K., Setoguchi S., Margulis A.V., Patrick A.R., Hernandez-Diaz S. (2012). Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants? Am J Epidemiol 175, 988-997.
129. Patkar, A.A., Bilal L., Masand P.S. (2004). Pharmacotherapy of depression in pregnancy. Ann Clin Psychiatry 16, 87-100.
130. Paulson, J.F., Keefe H.A., Leiferman J.A. (2009). Early parental depression and child language development. J Child Psychol Psychiatry 50, 254-262.
131. Pawluski, J.L. (2011). Perinatal Selective Serotonin Reuptake Inhibitor Exposure: Impact on Brain Development and Neural Plasticity. Neuroendocrinology.
132. Pawluski, J.L., Brain U.M., Underhill C.M., Hammond G.L., Oberlander T.F. (2012a). Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function. Psychoneuroendocrinology 37, 1019-1028.
133. Pawluski, J.L., Rayen I., Niessen N.A., Kristensen S., van Donkelaar E.L., Balthazart J., Steinbusch H.W., Charlier T.D. (2012b). Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience 220, 131-141.
134. Pineyro, G., Blier P. (1999). Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51, 533-591.
135. Pluess, M., Velders F.P., Belsky J., van Ijzendoorn M.H., Bakermans-Kranenburg M.J., Jaddoe V.W., Hofman A., Arp P.P., Verhulst F.C., Tiemeier H. (2011). Serotonin transporter polymorphism moderates effects of prenatal maternal anxiety on infant negative emotionality. Biol Psychiatry 69, 520-525.
136. Pollock, B.G., Ferrell R.E., Mulsant B.H., Mazumdar S., Miller M., Sweet R.A., Davis S., Kirshner M.A., Houck P.R., Stack J.A., Reynolds C.F., Kupfer D.J. (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23, 587-590.
137. Popa, D., Lena C., Alexandre C., Adrien J. (2008). Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J Neurosci 28, 3546-3554.
138. Qiu, C., Williams M.A., Calderon-Margalit R., Cripe S.M., Sorensen T.K. (2009). Preeclampsia risk in relation to maternal mood and anxiety disorders diagnosed before or during early pregnancy. Am JHypertens 22, 397-402.
139. Rahimi, R., Nikfar S., Abdollahi M. (2006). Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol 22, 571-575.
140. Rayen, I., Steinbusch H.W., Charlier T.D., Pawluski J.L. (2013). Developmental fluoxetine exposure and prenatal stress alter sexual differentiation of the brain and reproductive behavior in male rat offspring. Psychoneuroendocrinology.
141. Rayen, I., van den Hove D.L., Prickaerts J., Steinbusch H.W., Pawluski J.L. (2011). Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS ONE 6, e24003.
142. Reis, M., Kallen B. (2010). Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40, 1723-1733.
143. Romijn, H.J., Hofman M.A., Gramsbergen A. (1991). At what age is the developing cerebral cortex of the rat comparable to that of the full-term newborn human baby? Early Hum Dev 26, 61-67.
144. Ross, L.E., Grigoriadis S., Mamisashvili L., Vonderporten E.H., Roerecke M., Rehm J., Dennis C.L., Koren G., Steiner M., Mousmanis P., Cheung A. (2013). Selected Pregnancy and Delivery Outcomes After Exposure to Antidepressant Medication: A Systematic Review and Meta-analysis. JAMA Psychiatry 70, 436-443.
145. Sandman, C.A., Davis E.P. (2012). Neurobehavioral risk is associated with gestational exposure to stress hormones. Expert Rev EndocrinolMetab 7, 445-459.
146. Sari, Y., Zhou F.C. (2003). Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 21, 417-424.
147. Sarrias, M.J., Cabre P.M., Martinez E., Artigas F. (1990). Relationship between serotoninergic measures in blood and cerebrospinal fluid simultaneously obtained in humans. J Neurochem 5, 783-786.
148. Siiteri, P.K., Murai J.T., Hammond G.L., Nisker J.A., Raymoure W.J., Kuhn R.W. (1982). The serum transport of steroid hormones. Recent Prog Horm Res 38, 457-510.
149. Sikich, L., Hickok J.M., Todd R.D. (1990). 5-HT1A receptors control neurite branching during development. Brain Res Dev Brain Res 56, 269-274.
150. Simon, G.E., Cunningham M.L., Davis R.L. (2002). Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159, 2055-2061.
151. Simpson, K.L., Weaver K.J., de Villers-Sidani E., Lu J.Y., Cai Z., Pang Y., Rodriguez-Porcel F., Paul I.A., Merzenich M., Lin R.C. (2011). Perinatal antidepressant exposure alters cortical network function in rodents. Proc Natl Acad Sci U S A 108, 18465-18470.
152. Suri, R., Altshuler L., Hellemann G., Burt V.K., Aquino A., Mintz J. (2007). Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 164, 1206-1213.
153. Suri, R., Altshuler L., Hendrick V., Rasgon N., Lee E., Mintz J. (2004). The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 7, 193-200.
154. Tiemeier, H., Velders F.P., Szekely E., Roza S.J., Dieleman G., Jaddoe V.W., Uitterlinden A.G., White T.J., Bakermans-Kranenburg M.J., Hofman A., van IJzendoorn M.H., Hudziak J.J., Verhulst F.C. (2012). The Generation R Study: A review of design, findings to date, and a study of the 5-HTTLPR by environmental interaction from fetal life onward. J Am Acad Child Adolesc Psychiatry 51, 1119-1135.
155. Toh, S., Mitchell A.A., Louik C., Werler M.M., Chambers C.D., Hernandez-Diaz S. (2009a). Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 29, 555-560.
156. Toh, S., Mitchell A.A., Louik C., Werler M.M., Chambers C.D., Hernandez-Diaz S. (2009b). Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry 166, 320-328.
157. Van Batenburg-Eddes, T., Brion M.J., Henrichs J., Jaddoe V.W., Hofman A., Verhulst F.C., Lawlor D.A., Davey S.G., Tiemeier H. (2012). Parental depressive and anxiety symptoms during pregnancy and attention problems in children: a cross-cohort consistency study. J Child Psychol Psychiatry.
158. van den Berg, M.P., van der Ende J., Crijnen A.A., Jaddoe V.W., Moll H.A., Mackenbach J.P., Hofman A., Hengeveld M.W., Tiemeier H., Verhulst F.C. (2009). Paternal depressive symptoms during pregnancy are related to excessive infant crying. Pediatrics 124, e96-103.
159. Van den Hove, D., Jakob S.B., Schraut K.G., Kenis G., Schmitt A., Kneitz S., Scholz C.J., Wiescholleck V., Ortega G., Prickaerts J., Steinbusch H., Lesch K.P. (2011). Differential effects of prenatal stress in 5-Htt deficient mice: towards molecular mechanisms of gene x environment interactions. Plos One 6, e22715.
160. van den Hove, D.L., Blanco C.E., Scheepens A., Desbonnet L., Myint A.M., Leonard B.E., Prickaerts J., Steinbusch H.W. (2008). Prenatal maternal paroxetine treatment and neonatal mortality in the rat: a preliminary study. Neonatology 93, 52-55.
161. Ververs, T., Kaasenbrood H., Visser G., Schobben F., de Jong-van den Berg, Egberts T. (2006). Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62, 863-870.
162. Viau, V. (2002). Functional cross-talk between the hypothalamic-pituitary-gonadal and - adrenal axes. J Neuroendocrinol 14, 506-513.
163. Viau, V., Meaney M.J. (1991). Variations in the hypothalamic-pituitary-adrenal response to stress during the estrous cycle in the rat. Endocrinology 129, 2503-2511.
164. Vorhees, C.V., cuff-Smith K.D., Schilling M.A., Fisher J.E., Moran M.S., Buelke-Sam J. (1994). A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 23, 194-205.
165. Walsh, S., Ponten A., Fleischmann B.K., Jovinge S. (2010). Cardiomyocyte cell cycle control and growth estimation in vivo--an analysis based on cardiomyocyte nuclei. Cardiovasc Res 86, 365-373.
166. Weikum, W.M., Oberlander T.F., Hensch T.K., Werker J.F. (2012). Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proc Natl Acad Sci U S A 109 Suppl 2, 17221-17227.
167. Weissman, M.M., Pilowsky D.J., Wickramaratne P.J., Talati A., Wisniewski S.R., Fava M., Hughes C.W., Garber J., Malloy E., King C.A., Cerda G., Sood A.B., Alpert J.E., Trivedi M.H., Rush A.J. (2006). Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA 295, 1389-1398.
168. Wen, S.W., Yang Q., Garner P., Fraser W., Olatunbosun O., Nimrod C., Walker M. (2006). Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 194, 961-966.
169. Whitaker-Azmitia, P.M. (2001). Serotonin and brain development: role in human developmental diseases. Brain Res Bull 56, 479-485.
170. Wichman, C.L., Moore K.M., Lang T.R., St Sauver J.L., Heise R.H., Jr., Watson W.J. (2009). Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 84, 23-27.
171. Wilson, K.L., Zelig C.M., Harvey J.P., Cunningham B.S., Dolinsky B.M., Napolitano P.G. (2011). Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 28, 19-24.
172. Wisner, K.L., Sit D.K., Hanusa B.H., Moses-Kolko E.L., Bogen D.L., Hunker D.F., Perel J.M., Jones-Ivy S., Bodnar L.M., Singer L.T. (2009). Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 166, 557-566.
173. Wogelius, P., Norgaard M., Gislum M., Pedersen L., Munk E., Mortensen P.B., Lipworth L., Sorensen H.T. (2006). Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17, 701-704.
174. Xu, Y., Sari Y., Zhou F.C. (2004). Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Brain Res Dev Brain Res 150, 151-161.
175. Yavarone, M.S., Shuey D.L., Tamir H., Sadler T.W., Lauder J.M. (1993). Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 47, 573-584.
176. Yonkers, K.A., Norwitz E.R., Smith M.V., Lockwood C.J., Gotman N., Luchansky E., Lin H., Belanger K. (2012). Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology 23, 677-685.
177. Zeskind, P.S., Stephens L.E. (2004). Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113, 368-375.